UK markets close in 4 hours 32 minutes

Chugai Pharmaceutical Co., Ltd. (CHGCY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
19.92+0.17 (+0.86%)
At close: 03:59PM EST

Chugai Pharmaceutical Co., Ltd.

2-1-1 Nihonbashi-Muromachi
Chuo 103-8324
Japan
81 3 3281 6611
https://www.chugai-pharm.co.jp

Sector(s)Healthcare
IndustryDrug Manufacturers - General
Full-time employees7,604

Key executives

NameTitlePayExercisedYear born
Dr. Osamu OkudaPresident, CEO & Representative Director1.45MN/A1963
Mr. Toshiaki ItagakiHead of Finance Supervisory Division, CFO, Executive VP & DirectorN/AN/A1960
Toshiya SasaiExecutive of Investor Relations Group & Corporate Communications DepartmentN/AN/AN/A
Mr. Shinji HidakaExecutive VP and Head of Marketing & Sales DivisionN/AN/AN/A
Mr. Junichi EbiharaExecutive Vice PresidentN/AN/AN/A
Dr. Yoshiaki OhashiSVP & Full-time Audit Supervisory Board MemberN/AN/A1960
Mr. Tetsuya YamaguchiExecutive VP and Head of Project, Lifecycle Management & Foundation Medicine UnitN/AN/AN/A
Mr. Yoshiyuki YanoExecutive Vice PresidentN/AN/AN/A
Ms. Satoko ShisaiExecutive VP & Head of Digital Transformation UnitN/AN/A1963
Dr. Shigehiro Yamada Ph.D.Head of Sustainability Department & Full-Time Audit & Supervisory Board MemberN/AN/A1964
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

Corporate governance

Chugai Pharmaceutical Co., Ltd.’s ISS governance QualityScore as of 28 February 2024 is 6. The pillar scores are Audit: 1; Board: 7; Shareholder rights: 9; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.